Compugen
CGEN
Market cap $153M

1.71 USD

-0.02

1.16%

At close Oct 18, 4:00 PM EDT

After hours

1.71

+0.00

0.00%

1 day

-1.16%

5 days

-1.16%

1 month

-10.00%

3 months

-8.56%

6 months

-9.04%

Year to date

-14.50%

1 year

118.14%

5 years

-56.15%

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

204% more call options, than puts

Call options by funds: $750K | Put options by funds: $247K

1.42% less ownership

Funds ownership: 15.17% [Q1] → 13.75% (-1.42%) [Q2]

10% less funds holding

Funds holding: 73 [Q1] → 66 (-7) [Q2]

41% less capital invested

Capital invested by funds: $35M [Q1] → $20.7M (-$14.2M) [Q2]

56% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 27

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CGEN.

See Analyst Rankings

Financial journalist opinion

Compugen to Present New Clinical Data at SITC 2024

HOLON, Israel , Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that new clinical data supporting the anti-tumor activity and safety of the triple combination COM701, COM902 and pembrolizumb in heavily pre-treated patients with platinum resistant ovarian cancer will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 8-10, 2024, in Houston, Texas.

Compugen to Present New Clinical Data at SITC 2024

Zacks Investment Research

Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?

Compugen to Present at Single Cell Genomics 2024 Conference

HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd.

Compugen to Present at Single Cell Genomics 2024 Conference

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C.

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Zacks Investment Research

Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?

Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Compugen Ltd. (NASDAQ:CGEN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial Officer Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Stephen Willey - Stifel Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Partners Tony Butler - Rodman & Renshaw Operator Ladies and gentlemen, thank you for joining us today.

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates

Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago.

Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates

Compugen Reports Second Quarter 2024 Results

FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024 Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the Company Solid balance sheet with cash runway expected to fund operations into 2027 HOLON, Israel , Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd.

Compugen Reports Second Quarter 2024 Results

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer therapeutics as monotherapy and in combination in advanced solid tumors in Q4 2024 HOLON, Israel , July 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead Sciences, Inc. (Gilead).

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets open.

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

See News Rankings

Charts implemented using Lightweight Charts™